内表型
肥厚性心肌病
心肌病
生物
线粒体
心脏病学
肌节
内科学
遗传学
医学
神经科学
心肌细胞
心力衰竭
认知
作者
Hyemoon Chung,Yoonjung Kim,Sun-Mi Cho,Ho‐Joon Lee,Chul Hwan Park,Jong‐Youn Kim,Sang‐Hak Lee,Pil‐Ki Min,Young Won Yoon,Byoung Kwon Lee,Woo-Shik Kim,Bum‐Kee Hong,Tae Hoon Kim,Se‐Joong Rim,Hyuck Moon Kwon,Eui‐Young Choi,Kyung‐A Lee
出处
期刊:Mitochondrion
[Elsevier BV]
日期:2020-05-04
卷期号:53: 48-56
被引量:16
标识
DOI:10.1016/j.mito.2020.04.010
摘要
Hypertrophic cardiomyopathy (HCM) is a multigenic disease that occurs due to various genetic modifiers. We investigated phenotype-based clinical and genetic characteristics of HCM patients using comprehensive genetic tests and rare variant association analysis. A comprehensive HCM-specific panel, consisting of 82 nuclear DNAs (nDNAs: 33 sarcomere-associated genes, 5 phenocopy genes, and 44 nuclear genes linked to mitochondrial cardiomyopathy) and 37 mitochondrial DNAs (mtDNAs), was analyzed. Rare variant analysis was performed to determine the association of specific genes with different phenotypes. Among the 212 patients, pathogenic variants in sarcomere-associated genes were more prevalent in non-apical HCM (41.4%, 46/111; P = 0.001) than apical HCM (20.8%, 21/101). Apical HCM exhibits mild phenotypes than non-apical HCM, and it showed fewer numbers of sarcomere mutations than non-apical HCM. Interestingly, inverted mutation frequency of TNNI3 (35%) and MYH7 (9%) was observed in apical HCM. In a rare variant analysis, MT-RNR2 positively correlated with apical HCM (OR: 1.37, P = 0.025). And, MYBPC3 (sarcomere gene) negatively contributed to apical HCM (OR: 0.54, P = 0.027). On the other hand, both pathogenic mutation (P < 0.05) and rare variants in sarcomere-associated genes (OR: 2.78–3.47, P < 0.05) were related to diastolic dysfunction and left atrium remodeling, which correlated with poor prognosis in HCM patients. Our results provide a clue towards explaining the difference between the prevalence and phenotype of apical HCM in Asian populations, and a foundation for genetics-based approaches that may enable individualized risk stratification for HCM patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI